Clinical Trials Logo

Filter by:
NCT ID: NCT00013897 Completed - HIV Infections Clinical Trials

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

Start date: February 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC).

NCT ID: NCT00009737 Completed - Colorectal Cancer Clinical Trials

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

Start date: November 1998
Phase: Phase 3
Study type: Interventional

This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in combination with leucovorin, in patients who have undergone surgery for colon cancer. Patients will be randomized to receive either Xeloda 1250mg/m2 po bid on days 1-14 every 21 days, or leucovorin 20mg/m2 iv + 5-FU 425mg/m2 iv daily from day 1 to day 5 every 28 days. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00006249 Active, not recruiting - Melanoma (Skin) Clinical Trials

Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma

Start date: June 2000
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma. PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.

NCT ID: NCT00006230 Completed - Ovarian Cancer Clinical Trials

Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

Start date: May 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have advanced ovarian cancer.

NCT ID: NCT00006121 Terminated - Breast Cancer Clinical Trials

Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy

Start date: May 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating women who have advanced or metastatic breast cancer that has not responded to previous chemotherapy.

NCT ID: NCT00006026 Completed - Bladder Cancer Clinical Trials

Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract

Start date: May 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have metastatic cancer of the urinary tract.

NCT ID: NCT00005980 Completed - Breast Cancer Clinical Trials

Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Start date: April 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of liposomal doxorubicin is more effective for metastatic breast cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of liposomal doxorubicin in treating women who have metastatic breast cancer.

NCT ID: NCT00005918 Completed - HIV Infections Clinical Trials

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

Start date: June 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).

NCT ID: NCT00005589 Completed - Lymphoma Clinical Trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Start date: October 1999
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known if combination chemotherapy plus peripheral stem cell transplantation is more effective with or without rituximab for non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying giving combination chemotherapy and peripheral stem cell transplantation together with rituximab to see how well it works compared to combination chemotherapy and peripheral stem cell transplantation alone in treating patients with relapsed non-Hodgkin's lymphoma.

NCT ID: NCT00005062 Completed - Lung Cancer Clinical Trials

Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission

Start date: September 1999
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and prevent the spread of cancer to the brain. It is not yet known if standard-dose radiation therapy is more effective than high-dose radiation therapy in preventing the spread of limited-stage small cell lung cancer cells to the brain. PURPOSE: This randomized phase III trial is comparing two different regimens of radiation therapy to see how well they work in treating patients with limited-stage small cell lung cancer in complete remission.